<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Tue, 14 Apr 2026 18:14:21 -0400--><rss version="2.0">
    <channel>
        <title>Artelo Biosciences, Inc. (ARTL) Press Releases</title>
        <link>https://ir.artelobio.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/artelobio/files/theme/images/logo-sm.png</url>
                <title>Artelo Biosciences, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/184/artelo-biosciences-regains-compliance-with-nasdaq-listing</link>
                <pubDate>Tue, 07 Apr 26 07:50:00 -0400</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/184/artelo-biosciences-regains-compliance-with-nasdaq-listing</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/183/artelo-biosciences-announces-closing-of-11-0-million</link>
                <pubDate>Mon, 30 Mar 26 16:46:00 -0400</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/183/artelo-biosciences-announces-closing-of-11-0-million</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/182/artelo-biosciences-announces-11-0-million-private</link>
                <pubDate>Fri, 27 Mar 26 10:40:00 -0400</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/182/artelo-biosciences-announces-11-0-million-private</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/181/artelo-biosciences-expands-art27-13-development-as-a</link>
                <pubDate>Wed, 25 Mar 26 16:05:00 -0400</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/181/artelo-biosciences-expands-art27-13-development-as-a</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/178/artelo-announces-third-party-fully-funded-clinical-study</link>
                <pubDate>Wed, 18 Mar 26 07:41:00 -0400</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/178/artelo-announces-third-party-fully-funded-clinical-study</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Announces Reverse Stock Split]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/177/artelo-biosciences-announces-reverse-stock-split</link>
                <pubDate>Fri, 06 Mar 26 08:00:00 -0500</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/177/artelo-biosciences-announces-reverse-stock-split</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/176/artelo-biosciences-provides-business-update-highlighting</link>
                <pubDate>Tue, 24 Feb 26 08:00:00 -0500</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/176/artelo-biosciences-provides-business-update-highlighting</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/175/artelo-bioscience-commends-presidential-executive-order</link>
                <pubDate>Tue, 23 Dec 25 09:00:00 -0500</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/175/artelo-bioscience-commends-presidential-executive-order</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/174/artelo-biosciences-announces-publication-of-new</link>
                <pubDate>Wed, 03 Dec 25 08:30:00 -0500</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/174/artelo-biosciences-announces-publication-of-new</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.artelobio.com/news-events/press-releases/detail/173/artelo-biosciences-provides-business-update-and-reports</link>
                <pubDate>Wed, 12 Nov 25 08:00:00 -0500</pubDate>
                <guid>https://ir.artelobio.com/news-events/press-releases/detail/173/artelo-biosciences-provides-business-update-and-reports</guid>
                                                                            </item>
            </channel>
</rss>